Alterity Therapeutics announces positive results from its phase 2 trial of the drug ATH434 in MSA
On January 30th 2025, the pharmaceutical company Alterity Therapeutics announced positive data from their phase 2 placebo-controlled trial in early-stage MSA. MSA is a progressive neurological condition leading to impaired […]